# A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide

> **NCT05760313** · PHASE2 · COMPLETED · sponsor: **AbbVie** · enrollment: 19 (actual)

## Conditions studied

- Functional Constipation

## Interventions

- **DRUG:** Linaclotide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05760313
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-27
- **Primary completion:** 2025-06-09
- **Final completion:** 2025-06-09
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2026-01-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05760313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05760313, "A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05760313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*